New HER2 Drug for Breast Cancer Stalled by FDA

The FDA said it needs more data the new antibody-drug conjugate (ADC) trastuzumab duocarmazine for use in advanced or metastatic breast cancer.
Medscape Medical News

source https://www.medscape.com/viewarticle/992001?src=rss